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Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA)
after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver transplantation (OLT). However, follow-up in most
studies was short. We aimed to determine the long-term risk of HBV recurrence using this strategy. All HBV patients who
received 7 doses of intravenous HBIG after OLT, with no HBV recurrence while receiving HBIG, and who eventually
discontinued HBIG and were maintained on NA, were included. HBV recurrence was defined as HBsAg-positive or HBV DNA
5 log copies/mL on 2 consecutive occasions. Twenty-one patients met the inclusion criteria. Immediate post-OLT prophylaxis
was combination HBIG and NA in 15 patients, whereas 6 patients received HBIG monotherapy for 62-109 months before NA
was added. HBIG was discontinued a median of 26 (range, 0.2-121) months after OLT. Median follow-up post-HBIG
discontinuation was 40 (range, 5-51) months. Only 1 patient, who had 12 months of HBIG and was noncompliant to NA therapy,
had HBV recurrence, 34 months after HBIG discontinuation. One patient had HBV DNA of 3.3 log copies/mL 47 and 48 months
after HBIG discontinuation but remained HBsAg-negative. Lamivudine-resistant mutations were detected in both patients.
Probability of HBV recurrence was 0% and 9% at 2 and 4 years after HBIG discontinuation. Three patients had 1-2 episodes
of transiently detectable HBV DNA. All were HBV DNA and HBsAg negative on repeated tests over a period of 2-36 months.
Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence
after OLT in compliant HBV patients. Liver Transpl 13:374-381, 2007. © 2007 AASLD.
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Before the advent of antiviral prophylaxis, the progno-
sis of patients undergoing orthotopic liver transplanta-
tion (OLT) for hepatitis B virus (HBV)-related liver dis-
ease was poor because of the high (80-100%) rate of
graft reinfection after OLT.1,2 Recurrence of hepatitis B
in liver transplant recipients generally follows a more
aggressive course than in immunocompetent patients,
with a 2-year mortality of 50%. Fortunately, tremen-
dous strides in antiviral prophylactic measures have
been made in the last 20 years.3 The administration of
either high-dose intravenous (IV) hepatitis B immuno-
globulin (HBIG) or lamivudine (LAM) for an indefinite
duration after OLT have resulted in a marked reduction
in 3-year HBV recurrence rates to 15-25% for HBIG4-6
and 20-40% for LAM monotherapy.7-9 In recent years,
the combination of IV HBIG and LAM resulted in further
reduction in HBV recurrence rates to less than 10% up
to 3 years after OLT.6,10-13
However, IV HBIG is cumbersome to administer and
expensive, with estimated costs of US$100,000 in the
first year after OLT and US$50,000 in each subsequent
year.14 The cost of HBIG is lower in many countries
outside the United States but remains substantial.14,15
Therefore, long-term HBIG therapy poses a huge eco-
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nomic burden on patients and on the health care sys-
tem. Several studies have attempted to replace long-
term HBIG with active immunization after varying
durations of HBIG, with conflicting results.16-19 Others
have tried to lower the cost of HBIG by administering it
intramuscularly (IM) at lower doses.20-25 Finally, other
investigators have tried to discontinue HBIG altogether
after the initial post-OLT period and continue with an-
tiviral monotherapy in patients at low risk for HBV
recurrence (hepatitis B e antigen [HBeAg] negative with
undetectable HBV DNA by non–polymerase chain reac-
tion [PCR]-based assays at transplant), with recurrence
rates varying from 0 to 16%.26-28 These results are
encouraging and may lead to cost-effective strategies
permitting HBIG discontinuation in a select group of
patients. However, the duration of follow-up after HBIG
discontinuation in these studies was short (13-17
months). Thus, it is unclear if antiviral therapy alone
will be sufficient in the long-term prevention of HBV
recurrence after OLT.
A controlled trial of 29 patients initially provided com-
bination HBIG and LAM therapy for 1 month after OLT,
then randomized to 17 months of LAM monotherapy
(n  14) or combination therapy (n  15) showed excel-
lent results with no recurrence 18 months after OLT.28
However, a follow-up report later indicated that 4 pa-
tients, all of whom were receiving LAM monotherapy,
eventually experienced HBV recurrence after 5 years of
follow-up.29 Another study found that HBV DNA per-
sisted in the liver, peripheral blood mononuclear cells,
and/or sera of 55% of patients who had been followed
for 10 years after OLT with undetectable serum HBsAg
while receiving HBIG therapy.30 In these patients, overt
HBV recurrence may have been suppressed by the
presence of circulating hepatitis B surface antibodies.
Thus, there is a possibility that HBV recurrence may
manifest after discontinuation of HBIG, particularly in
patients who have received LAM for many years.
The aims of the current study were to determine the
rate of HBV recurrence in OLT recipients who were
receiving maintenance nucleos(t)ide analogue (NA)
therapy at the time HBIG was discontinued, and to
identify pre- and post-OLT factors that are predictive of
HBV recurrence in these patients.
METHODS
All patients who underwent OLT due to HBV-induced
liver disease at the University of Michigan Health Care
System between January 1, 1994, and December 31,
2005, and who had received at least 7 doses of high-
dose (10,000 U) IV HBIG immunoprophylaxis after OLT
with at least 3 months of follow-up after HBIG discon-
tinuation were included. Patients who experienced HBV
recurrence while receiving HBIG and patients who died
while still receiving HBIG were excluded. This retro-
spective study was approved by our institutional review
board.
Between 1994 and 1998, HBV prophylaxis at our
center consisted of high-dose IV HBIG monotherapy
(10,000 IU anhepatic, daily during the first week, and
then monthly thereafter). In 1998, oral antiviral therapy
consisting of LAM was administered before OLT to pa-
tients with detectable HBV DNA by hybridization assay
or 4-5 log copies/mL by PCR assay and continued
after OLT in conjunction with high-dose IV HBIG. In
2001, patients who had been followed for more than 1
year after OLT with no HBV recurrence were enrolled
onto a study where the route of administration of HBIG
was switched from IV to IM (1,000 U monthly) for 1 year,
after which HBIG was discontinued and patients re-
ceived maintenance antiviral therapy.31 LAM was
added when the HBIG administration route was
switched from IV to IM in patients who were not receiv-
ing it at that time. In 2002, patients who were HBeAg
negative with serum HBV DNA 5 log copies/mL at the
time of OLT were enrolled onto a study where they
received only 7 doses of IV HBIG after OLT (10,000 IU
during the anhepatic and reperfusion phases, and
10,000 IU daily for 5 more days) while being maintained
on NA therapy. Since 2003, patients with virologic
breakthrough while receiving LAM received additional
treatment with adefovir (ADV) or were switched from
LAM to ADV monotherapy. All patients were tested for
HBsAg and HBV DNA every month during the first year
after OLT, every 3 months during years 2 and 3, and
every 3-6 months thereafter.
Initial post-OLT immunosuppression consisted of
prednisone, azathioprine, or mycophenolate mofetil,
and tacrolimus or cyclosporine. Prednisone was discon-
tinued 3-6 months after OLT; azathioprine or mycophe-
nolate mofetil was discontinued 6-12 months after OLT.
Medical records of eligible patients were reviewed.
Demographic data, indication for OLT, dose and route
of HBIG administration, and type and duration of anti-
viral therapy were recorded. Antibodies to hepatitis C
virus and hepatitis D virus were determined at the time
of listing. HBV markers (hepatitis B surface antigen
[HBsAg], HBeAg, antibody to HBeAg [anti-HBe], HBV
DNA, and hepatitis B surface antibody titers), hematol-
ogy and chemistry results (blood counts, prothrombin
time expressed as international normalized ratio of pro-
thrombin time, albumin, total bilirubin, alkaline phos-
phatase, alanine and aspartate aminotransferases, and
creatinine) at the time of listing for OLT, initiation of
antiviral therapy, OLT, HBIG discontinuation, and ev-
ery 6 months after HBIG was withdrawn were recorded.
In addition, HBsAg and HBV DNA were tested every 1-3
months the first year after HBIG was withdrawn, and
every 3-6 months thereafter. Since April 2003, serum
HBV DNA was tested by PCR-based assays with lower
limit of detection of 1.5-2.5 log copies/mL. Results from
our center’s laboratory were used in the analysis when
available. Otherwise, results from outside laboratories
were used.
HBV resistance mutations were determined in pa-
tient samples with detectable HBV DNA by direct se-
quencing of the HBV S and P genes at the DNA core
sequencing facility of the University of Michigan Medi-
cal Center and by a line probe assay (INNO-Lipa DRv2;
Innogenetics NV, Ghent, Belgium).32
HBV RECURRENCE AFTER HBIG WITHDRAWAL 375
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
Study End Point
The end point of the study was HBV recurrence, defined
as the presence of positive serum HBsAg or serum HBV
DNA 5 log copies/mL (or detectable by hybridization
assays) on 2 consecutive occasions.
Statistical Analysis
Continuous variables are expressed as mean  SD un-
less specified otherwise. Categorical data are presented
as number (percent). Kaplan-Meier analysis was used
to estimate the cumulative probability of HBV recur-
rence. P values 0.05 were considered statistically sig-
nificant.
RESULTS
A total of 886 liver transplantations were performed
between January 1994 and December 2005 at our cen-
ter, of which 40 (4.5%) were performed for HBV-related
liver disease. Nineteen patients were excluded because
of HBV recurrence (n  4) and death while still receiving
HBIG (n  10), were still receiving HBIG at the time of
analysis (n  2), or were lost to follow-up (n  3).
Twenty-one patients (17 men) met the inclusion crite-
ria. The mean age at the time of transplant was 48.6 
9.6 years. Eighteen patients received transplants for
decompensated cirrhosis and 3 for hepatocellular car-
cinoma. At the time of OLT, only 3 of 15 patients tested
had serum HBV DNA 5 log copies/mL, and 5 of 16
patients tested were positive for HBeAg (Table 1). Pa-
tient 7 had hepatitis C virus coinfection; patient 21 had
both hepatitis C and D virus coinfection.
Eleven patients began LAM therapy 1-40 (median, 20)
months before OLT, and all but one continued to receive
LAM after OLT. Patient 8 experienced LAM break-
through and was switched to ADV monotherapy 7
months before OLT, and continued to receive ADV after
OLT. None of the patients cleared HBsAg while receiving
antiviral therapy before OLT. The remaining 10 patients
were either started on LAM immediately after OLT (n 
4) or after a median of 82 (range, 62-109) months after
OLT (n  6) as part of a prospective HBIG withdrawal
protocol31 (Table 2).
All patients received IV HBIG during the anhepatic
phase and the first week after OLT. Three patients (pa-
tients 9, 17, and 18) who were deemed to be low-level
replicators before OLT stopped HBIG after the first week
after OLT. Among the 18 patients who continued to
receive monthly IV infusions of HBIG, 15 received a
median of 20 (range, 9-110) months of IV HBIG and
were then switched to low-dose IM HBIG for 3-15 (me-
dian, 12) months before HBIG was discontinued,
whereas the remaining 3 patients received 11-13
TABLE 1. Characteristics of Patients at Time of Transplantation













1 47 M White Cirrhosis NA Negative LAM 3
2 51 M White Cirrhosis Negative* Negative LAM 19
3 60 F Asian Cirrhosis NA Negative LAM 30
4 40 M White Cirrhosis 5.7 Negative LAM 28
5 39 M White HCC 7 Positive LAM 1
6 25 M White Cirrhosis Negative* Negative LAM 10
7 52 M White HCC 4.7 NA LAM 4
8 52 M Asian Cirrhosis 3.5 Positive LAM3ADV 40
9 57 F White Cirrhosis Negative† Negative LAM 35
10 56 M White Cirrhosis 2.5 Negative LAM 20
11 55 M White Cirrhosis Negative† Negative LAM 27
12 65 M White Cirrhosis NA Positive NA NA
13 51 F White Cirrhosis NA NA NA NA
14 53 M White Cirrhosis Negative* Negative NA NA
15 34 M White Cirrhosis NA NA NA NA
16 41 M White Cirrhosis NA NA NA NA
17 51 M White Cirrhosis 4.3 Negative NA NA
18 48 M White HCC Negative† Negative NA NA
19 44 F White Cirrhosis 4 Positive NA NA
20 59 M White Cirrhosis Positive* Positive NA NA
21 40 M White Cirrhosis NA NA NA NA
Abbreviations: OLT, orthotopic liver transplant; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; NA, not available; LAM,
lamivudine; ADV, adefovir.
*HBV DNA tested by hybridization.
†HBV DNA tested by polymerase chain reaction assay.
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months of IV HBIG before it was discontinued. Four
patients discontinued HBIG during year 1 (3 were
deemed to be low-risk patients [patients 9, 17, and 18],
and 1 missed the month 12 dose of HBIG [patient 19]),
4 in years 2-3, and 13 after year 3. The median duration
of HBIG therapy (IV and IM) for the whole cohort was 26
(range, 0.2-121) months. At the time of HBIG discon-
tinuation, all patients were negative for HBsAg and se-
rum HBV DNA by PCR assay. None of the patients
received treatment for acute rejection. Apart from the 3
patients who received only 1 week of HBIG, all patients
had stopped receiving prednisone at the time HBIG was
discontinued.
Outcomes
Median follow-up after HBIG discontinuation was 40.2
(range, 4.5-51.1) months. The number of patients fol-
lowed for more than 12, 24, 36, and 48 months after
HBIG discontinuation were 18, 15, 11, and 6, respec-
tively. All patients were still alive at the time of analysis.
A single patient (patient 1) developed HBV recur-
rence, with positive serum HBsAg and an HBV DNA of
7.9 log copies/mL at 34.2 months after HBIG discon-
tinuation. This patient began LAM treatment 3 months
before OLT and had an HBV DNA level of 3.5 log cop-
ies/mL and negative serum HBeAg at the start of LAM
treatment. HBV DNA was not determined at the time of
transplantation. After OLT, this patient initially re-
ceived a combination of IV HBIG and LAM for 9 months,
after which IV HBIG was switched to IM HBIG because
of lack of insurance coverage. After 3 months on IM
HBIG and LAM, this patient was lost to follow-up de-
spite numerous attempts to contact the patient. This
patient was not seen in the clinic, and no laboratory
results were available between 12 and 46 months after
OLT. At month 46 after OLT, this patient returned to
clinic with fatigue but had no evidence of hepatic de-
compensation. Laboratory tests showed the following:
alanine aminotransferase 164 U/L, bilirubin 1 mg/dL,
positive serum HBeAg and HBsAg, and serum HBV
DNA 7.9 log copies/mL. This patient claimed to have
continued LAM throughout, but admitted to stopping
HBIG after month 12. Resistance testing performed at
the time of HBV recurrence revealed the presence of
LAM-resistant mutations (leucine to methionine substi-















Type Onset of therapy HBsAg HBV DNA
1 LAM3LAMADV* Pre-OLT 12 Yes 45 Detected† 5 log copies/mL†
2 LAM3FTCTDF‡ Pre-OLT 26 Yes 50 UD§ 3 log copies/mL†
3 LAM Pre-OLT 45 Yes 13 UD UD
4 LAM Pre-OLT 12 No 40 UD UD
5 LAM Pre-OLT 42 Yes 46 UD UD
6 LAM Pre-OLT 33 Yes 48 Transient UD
7 LAM Pre-OLT 25 Yes 34 UD UD
8 ADV Pre-OLT 26 Yes 5 UD UD
9 LAM Pre-OLT 0.2 No 32 UD UD
10 LAM Pre-OLT 24 Yes 6 UD Transient
11 LAM Pre-OLT 13 No 24 UD Transient
12 LAM Month 62 after OLT 75 Yes 51 UD Transient
13 LAM Month 91 after OLT 103 Yes 16 UD UD
14 LAM Immediately after OLT 31 Yes 29 UD UD
15 LAM Month 99 after OLT 111 Yes 13 UD UD
16 LAM Month 109 after OLT 121 Yes 9 UD UD
17 LAM Immediately after OLT 0.2 No 51 UD UD
18 LAM Immediately after OLT 0.2 No 44 UD UD
19 LAM Immediately after OLT 11 No 47 UD UD
20 LAM Month 67 after OLT 79 Yes 50 UD UD
21 LAM Month 73 after OLT 85 Yes 51 UD UD
Abbreviations: OLT, orthotopic liver transplant; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV,
hepatitis B virus; LAM, lamivudine; FTC, emtricitabine; TDF, tenofovir; ADV, adefovir; UD, undetectable; PCR, polymerase
chain reaction.
*ADV added to LAM at time of HBV recurrence.
†On 2 or more occasions.
‡LAM switched to FTC  TDF when LAM resistance was confirmed.
§UD indicates consistently negative HBsAg or HBV DNA by PCR-based assays.
PTransient detection of HBV DNA (with negative HBsAg) or HBsAg (with negative HBV DNA). All patients were negative for HBV
DNA and HBsAg at last follow-up.
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tution at codon 180 [rtL180M], methionine to valine at
codon 204 [rtM204V], and valine to leucine at codon
173 [rtV173L] of the polymerase gene). Mutations in the
“a” determinant of the HBV surface protein were not
detected. ADV was added to LAM and serum HBV DNA
decreased to 5.4 log copies/mL and alanine amino-
transferase to 47 U/L 4 months later. The cumulative
probability of developing HBV recurrence was 0%, 0%,
9.1%, and 9.1% at 1, 2, 3, and 4 years after HBIG
discontinuation, respectively.
One patient (patient 2) had transiently detectable but
unquantifiable HBV DNA (2.3 log copies/mL) on one
occasion 16 months after HBIG discontinuation. HBV
DNA was undetectable on 9 subsequent occasions.
However, HBV DNA became detectable again at 3.3 log
copies/mL 46.6 months after HBIG discontinuation.
This patient had no symptoms and had negative serum
HBsAg and normal liver chemistries. He was compliant
with follow-up and insisted that he never missed a
single dose of LAM. Repeat tests a month later showed
that serum HBV DNA remained detectable at the same
level, but HBsAg was still not detected, and liver chem-
istries were normal. Resistance testing revealed the
presence of LAM-resistant mutations (rtL180M and
rtM204V), and antiviral therapy was switched to a com-
bination of emtricitabine and tenofovir. This patient
was HBeAg-positive with HBV DNA of 6.2 log copies/mL
when LAM was started 19 months before OLT, with loss
of HBeAg and undetectable serum HBV DNA by hybrid-
ization assay at the time of OLT.
Two patients (patients 10 and 12) had 1 episode and
one patient had 2 episodes (patient 11) of transiently
detectable HBV DNA as assessed by PCR-based assays
after HBIG was discontinued, but with negative HBsAg.
These 3 patients denied missing any dose of LAM and
had no change in immunosuppressive therapy at the
time of transient HBV DNA detection. All instances of
detectable HBV DNA were 3 log copies/mL except for
one occasion in a single patient (3.8 log copies/mL;
patient 10). Serum samples were available in 2 of 4
instances, and resistance testing did not detect the
presence of antiviral drug–resistant mutations. All 3
patients remained HBsAg negative with normal liver
chemistries throughout. Each patient had HBV DNA
and HBsAg retested a median of 5 (range, 1-6) times
over a period of 2-36 months since the last detectable
HBV DNA, with undetectable HBV DNA and HBsAg on
all occasions. One patient (patient 6) had detectable
HBsAg once 9 months after HBIG discontinuation, but
HBV DNA was persistently undetectable with normal
liver chemistries. This patient was repeatedly negative
for HBsAg up to the last visit, 39 months after the
transient detection of HBsAg. The remaining 15 pa-
tients remained HBsAg negative with undetectable HBV
DNA and normal liver chemistries throughout the fol-
low-up period, 5-51 months after HBIG was stopped.
DISCUSSION
Our data demonstrate that discontinuing HBIG in the
presence of maintenance therapy with an NA was asso-
ciated with a low risk of HBV recurrence (9%) during a
median follow-up of 40 months. The lone patient who
experienced HBV recurrence in our study was noncom-
pliant and was lost to follow-up for an extended period
of time. None of the compliant patients developed HBV
recurrence. Our data are consistent with earlier pub-
lished reports where the duration of follow-up after
HBIG withdrawal was shorter than in our study.26-28,33
Dodson et al.26 prospectively followed 16 patients who
were switched to LAM monotherapy after 24 months of
IV HBIG. No HBV recurrence was noted a median of 13
months after HBIG was stopped. One study from Eu-
rope randomized 24 patients to receive either HBIG or
LAM monoprophylaxis after at least 6 months of HBIG
monotherapy. HBV recurrence occurred in 2 of 12 pa-
tients in the LAM group; both had received 12 months
of HBIG before being switched to LAM monoprophy-
laxis.27 Two other studies used relatively short dura-
tions of LAM and HBIG combination therapy (1-4
weeks) followed by LAM monotherapy, with HBV recur-
rence rates of 0-10% at 18 months after OLT.28,33 Two
reports published as abstracts showed higher rates of
recurrence after longer follow-up. Buti et al.29,34 fol-
lowed up on their initial report and showed an HBV
recurrence rate of 19% (4 of 21) in patients maintained
on LAM monotherapy 5 years after OLT. Two of their
patients who developed recurrence were noncompliant.
Similarly, Wang et al.35 reported HBV recurrence rates
of 15% vs. 9% at 5 years after OLT in patients given 6 
2 vs. 12  2 months of combination HBIG and antiviral
therapy, respectively, followed by antiviral mono-
therapy.
Discontinuing HBIG therapy after the first 2-3 years
after OLT may translate into marked reduction in
health care costs for HBV patients who undergo OLT.
Although there is a wide range in the dose of HBIG used
across different transplant centers and a marked vari-
ation in the price of HBIG in different countries,14,15 the
costs of indefinite HBIG therapy remain high. Esti-
mated charges for 1 year of IV (10,000 U/mo) and IM
(1,000 U/mo) HBIG therapy in our center are
US$125,000 and US$36,000 per patient, respectively.
In comparison, the estimated costs for 1 year of LAM,
ADV, or entecavir are US$2,800, US$7,700 and
US$8,500, respectively (http://www.drugstore.com/).
A recent cost-effective analysis suggested that the use
of LAM monotherapy with ADV rescue for recurrence
resulted in substantial savings per HBV recurrence
prevented over a regimen of indefinite IV or IM HBIG
with LAM.14 However, this was at the expense of a
higher HBV recurrence rate in patients provided LAM
monotherapy. A strategy involving a finite course of
combination HBIG and NA followed by maintenance NA
therapy would be more cost-effective if the HBV recur-
rence rate is similar to prophylaxis with indefinite com-
bination of HBIG and NA.
The increased availability of highly sensitive PCR-
based HBV DNA assays has enabled the detection of
low amounts of virus in post-OLT patients with no se-
rologic evidence of HBV reinfection (undetectable se-
rum HBsAg). From a purely virological standpoint, the
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reappearance of serum HBV DNA may be interpreted as
an early sign of HBV recurrence, as it is possible that
detection of HBV DNA may precede the reappearance of
serum HBsAg.36 Several studies have reported that
HBV DNA can be detected in the liver, peripheral blood
mononuclear cells, or sera of post-OLT patients who
have no serologic evidence of HBV reinfection, indicat-
ing that some of these patients may have occult or
subclinical reinfection.4,13,27,28,30 However, serum
HBV DNA can also be detected, albeit in low concentra-
tions, in patients who have spontaneously recovered
from acute HBV infection.37 Therefore, the question
remains as to whether the detection of any level of
serum HBV DNA in post-OLT patients should be taken
as an early sign of HBV recurrence. In our series, HBV
DNA was detected transiently in 4 patients, of whom 3
remained negative for HBV DNA by PCR a median of 12
months after the last detection of HBV DNA, and HBsAg
remained negative with normal liver chemistries. This
confirms previous reports that transient detection of
low levels of serum HBV DNA after OLT may not neces-
sarily signify HBV recurrence and emphasizes the need
for serial monitoring.13,27 The fourth patient (patient 2)
had detectable serum HBV DNA of 3.3 log copies/mL on
2 consecutive occasions. Sequencing of the HBV ge-
nome in this patient revealed the presence of LAM-
resistant mutations, so therapy was switched from LAM
to combination of emtricitabine and tenofovir.
The significance of the detection of antiviral-resistant
mutations in post-OLT patients who test negative for
HBsAg has been questioned.27,38 Naoumov et al.27
showed that HBsAg and HBV DNA (hybridization assay)
remained negative 10-22 months after the initial detec-
tion of LAM-resistant mutations in 3 of their post-OLT
patients who continued LAM monotherapy after the
discontinuation of HBIG. However, these patients had
very low level viremia (2.5-2.7 log copies/mL) when
LAM-resistant mutations were detected. The decreased
replication fitness of LAM-resistant mutants may ac-
count for the low HBV DNA level and undetectable HB-
sAg when the mutants first emerge. In addition, some
mutations in the polymerase gene lead to changes in
the overlapping surface gene that may decrease recog-
nition of the surface protein in serology assays resulting
in false negative HBsAg test results.39 Regardless, con-
tinuation of LAM may eventually select for additional
mutations that restore replication fitness of LAM-resis-
tant mutants leading to virus rebound, hepatitis flares,
and hepatic failure.40-42 Furthermore, severe hepatitis
flares and death can occur in patients who develop LAM
resistance after OLT.42-45 Therefore, initiation of rescue
therapies seems prudent in post-OLT patients who
have persistent detection of antiviral-resistant HBV.
Our favorable results may not be applied to all HBV
patients. Most (67%) of our patients had received 24
months of HBIG before it was discontinued. In addition,
most patients were not receiving corticosteroids and
were receiving a single calcineurin inhibitor when HBIG
was withdrawn. Although none of the 4 patients who
received 12 months of HBIG therapy in our study
experienced HBV recurrence, all of them had low virus
replication immediately before OLT (5 log copies/mL),
making them less likely to experience HBV recurrence.
Therefore, it is unknown whether the same results can
be achieved in patients who stopped HBIG earlier, and
in those with high virus replication before OLT. Unlike
most studies on HBIG discontinuation, where most pa-
tients were at low risk for HBV recurrence after OLT
(HBeAg-negative and negative HBV DNA by hybridiza-
tion assay),26-28 we included 6 patients (29%) who
would have been considered high risk at the time of OLT
(Table 1). On the other hand, we acknowledge that by
excluding patients who experienced HBV recurrence
while they were still receiving HBIG, we may have se-
lected for patients who are less likely to have HBV re-
currence regardless of HBIG discontinuation. Addi-
tional prospective randomized studies are needed to
define the optimal timing and to identify the best can-
didates for HBIG withdrawal.
In conclusion, we have demonstrated excellent long-
term results in compliant patients in whom HBIG was
discontinued after 24 months after OLT. It is possible
that similar results can be obtained in patients given a
shorter duration of HBIG therapy after OLT with the
use of newer antiviral therapies, such as entecavir, that
are more potent and have lower rates of drug resis-
tance. We found that transient detection of low-level
serum HBV DNA is not uncommon and is not neces-
sarily associated with HBV recurrence. However, per-
sistent detection of HBV DNA levels of 3 log copies/mL
and the detection of antiviral therapy–resistant muta-
tions may be harbingers of HBV recurrence and may
warrant intervention before reappearance of HBsAg in
order to prevent hepatitis flares.
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